K. Durga Prasanna Roja, B. Kumar*, M. Gobinath
Department of Pharmacy Practice, Ratnam Institute of Pharmacy, Pidathapolur, Nellore, Andhra Pradesh, India-524346
A B S T R A C T
Systemic lupus erythematosus (SLE) is an autoimmune disease in which organs and cells undergo damage initially mediated by tissue-binding auto antibodies and immune complexes. The treatment of SLE is highly individualized because of its diversity of clinical manifestations. Patients are treated according to the clinical manifestations they develop with different drugs like steroids, immunosuppressant’s etc. The comorbidities which increase the risk of morbidity and mortality in SLE patients according to EULAR are infections, hypertension, dyslipidemia, atherosclerosis, coronary artery disease, diabetes mellitus, osteoporosis, avascular necrosis of bone, malignancies. One hundred and thirty two patients with SLE treated at Tertiary care Hospital, Nellore during October 2014- August 2015were collected from MRD. Among them 93 patients were enrolled into the study based on the inclusion and exclusion criteria. The demographic details of all patients admitted were presented in table 1. The mean age of 93 patients was 30.60 ± 8.83 years. The study population consisted of 87 females and 6 males (15:1.9) with an average age of 29.3±8.5 years at the onset of the disease. Gender wise distribution is presented in figure 1. 8.6% of the patients had a family history of the SLE. Among the various co-morbid conditions observed in SLE patient’s hypertension was seen in 6.5% followed by hypothyroidism (5.4%).
Keywords: SLE, EULAR, MRD, Co-morbid.